Metastatic squamous cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:33:06 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Metastatic squamous cell carcinoma – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Chemotherapy with Cisplatin, Fluorouracil, and Docetaxel for Patients with Locally Advanced Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-on-chemotherapy-with-cisplatin-fluorouracil-and-docetaxel-for-patients-with-locally-advanced-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:30:07 +0000 https://clinicaltrials.eu/trial/study-on-chemotherapy-with-cisplatin-fluorouracil-and-docetaxel-for-patients-with-locally-advanced-squamous-cell-carcinoma/ This clinical trial is focused on studying a type of cancer called squamous cell carcinoma, which can occur in areas such as the mouth, throat, and voice box. The study is investigating a combination of three chemotherapy drugs: cisplatin, 5-fluorouracil (also known as 5-FU), and docetaxel. These medications are used to treat cancer by stopping the growth of cancer cells. The purpose of the study is to evaluate how effective this combination of drugs is in treating the cancer while minimizing side effects.

Participants in the study will receive the chemotherapy drugs through an intravenous infusion, which means the medication is given directly into a vein. The treatment will be administered over a period of several weeks, with the specific schedule and doses adjusted to suit each participant’s needs. Some participants may receive a placebo as part of the study. The study aims to monitor the response to treatment and any side effects that may occur.

The trial will assess various outcomes, including the success rate of the treatment after eight weeks, overall survival, and the ability to control the cancer locally. It will also look at the preservation of the voice box and the absence of cancer spread to other parts of the body. Additionally, the study will evaluate the quality of life of participants using specific questionnaires. The trial is designed to provide valuable information on the effectiveness and safety of this chemotherapy combination for patients with locally advanced squamous cell carcinoma.

]]> Study on the Safety and Effects of Durvalumab and Tremelimumab with Radiotherapy for Patients with Metastatic Squamous Cell Carcinoma https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-durvalumab-and-tremelimumab-with-radiotherapy-for-patients-with-metastatic-squamous-cell-carcinoma/ Wed, 29 Apr 2026 14:27:31 +0000 https://clinicaltrials.eu/trial/study-on-the-safety-and-effects-of-durvalumab-and-tremelimumab-with-radiotherapy-for-patients-with-metastatic-squamous-cell-carcinoma/ This clinical trial is focused on studying a type of cancer called metastatic squamous cell carcinoma, which can occur in areas such as the head and neck, lungs, esophagus, cervix, vagina, vulva, or anus. The study is testing a combination of treatments to see how safe and effective they are. The treatments being tested include two medications: Durvalumab (also known by its code name MEDI4736) and Tremelimumab. These medications are given together with a type of radiation therapy called stereotactic body radiotherapy (SBRT), which is a precise form of radiation treatment.

The purpose of the study is to evaluate the safety and clinical activity of these treatments when used together. Participants in the study will receive the medications and radiation therapy, and their health will be monitored to see how their cancer responds to the treatment. The study will also look at any side effects that may occur. The trial is divided into two phases: the first phase focuses on safety, while the second phase looks at how well the treatment works in reducing cancer outside the area that receives radiation.

Throughout the study, participants will undergo various medical assessments, including imaging tests like CT scans, to track the progress of their cancer and any changes in their condition. The study aims to provide valuable information on the potential benefits and risks of using Durvalumab and Tremelimumab in combination with SBRT for treating this type of cancer.

]]>